Robot‐assisted vs open inferior vena cava thrombectomy: a comparative analysis of perioperative and oncological outcomes
OBJECTIVES: To compare the perioperative and oncological outcomes between open inferior vena cava (IVC) thrombectomy (OP-IVCT) and robot-assisted IVCT (RA-IVCT) for renal tumours with Mayo levels I-IV IVC thrombi. PATIENTS AND METHODS: We retrospectively evaluated patients who underwent radical nephrectomy with IVCT between January 2006 and December 2023 at a high-volume centre. The patients were stratified according to the surgical approach (OP-IVCT vs RA-IVCT). Primary analysis was performed in the full cohort using multivariable regression models, with surgical approach as a covariate. The key perioperative outcomes, postoperative complications, disease-free survival (DFS), and overall survival (OS) were evaluated. Propensity score matching (PSM) at a one-to-one ratio was performed as a sensitivity analysis. RESULTS: Of the 226 patients, 37 underwent OP-IVCT and 189 underwent RA-IVCT. In the full-cohort multivariable analyses, RA-IVCT was independently associated with lower estimated blood loss (adjusted ratio 0.472, P < 0.001), shorter postoperative hospital stay (adjusted ratio 0.798, P = 0.027), reduced intraoperative transfusion (adjusted odds ratio [OR] 0.065, P = 0.002), and fewer postoperative complications (adjusted OR 0.162, P = 0.007). The operative time and intensive care unit transfer did not differ significantly between the groups. The surgical approach was not independently associated with OS (adjusted hazard ratio [HR] 1.019, P = 0.969) or DFS (adjusted HR 0.782, P = 0.528). After PSM, 37 matched pairs were analysed. The matched analysis confirmed lower estimated blood loss, reduced transfusion requirement, shorter hospital stay, and fewer postoperative complications with RA-IVCT, whereas OS and DFS remained statistically comparable between the groups. CONCLUSION: RA-IVCT is a safe and effective alternative to OP-IVCT for patients with renal tumours and IVC tumour thrombi. No evidence of inferior intermediate-term oncological outcomes was observed for RA-IVCT.
Authors
- Liangyou Gu (ORCID: https://orcid.org/0000-0001-9275-259X)
- Qilong Jiao (ORCID: https://orcid.org/0000-0003-0588-7408)
- Qingbo Huang (ORCID: https://orcid.org/0000-0003-2894-0187)
- Jialong Song (ORCID: https://orcid.org/0000-0002-4233-8005)
- Xu Zhang (ORCID: https://orcid.org/0000-0002-0608-6509)
- Xin Ma (ORCID: https://orcid.org/0000-0001-8257-4670)
- Xinlin Peng
- Teng Su
- Xinran Chen
- Jiayi Chen
- Chenzhi Zhao (ORCID: https://orcid.org/0009-0004-6725-9807)
- Cheng Peng (ORCID: https://orcid.org/0000-0002-0613-040X)
- Yibo Chen
- Xuanyu Bai (ORCID: https://orcid.org/0009-0008-2886-3154)
- Changwei Shi
Institutions
- Nankai University (CN)
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1111/bju.70542
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation